Show simple item record

dc.contributor.authorVasalakumari, Remya
dc.contributor.authorPandya, Abilash D
dc.contributor.authorPettersen, Solveig J.
dc.contributor.authorKvalvaag, Audun Sverre Myrset
dc.contributor.authorMyrann, Anne-Grethe
dc.contributor.authorGhiarasim, Razvan
dc.contributor.authorRotaru, Alexandru
dc.contributor.authorDimofte, Mihail-Gabriel
dc.contributor.authorSkotland, Tore
dc.contributor.authorSandvig, Kirsten
dc.contributor.authorMælandsmo, Gunhild Mari
dc.contributor.authorIversen, Tore Geir
dc.date.accessioned2025-08-15T11:05:17Z
dc.date.available2025-08-15T11:05:17Z
dc.date.issued2025-07-28
dc.description.abstractBreast cancer positive for human epidermal growth factor receptor-2 (HER2) is challenging to treat due to the development of drug resistance, even with recently developed antibody-mediated therapeutics. However, nanotechnology provides new innovative therapeutic strategies. This study evaluates the efficacy of new HER2-targeted, pH-sensitive poly(ethylene glycol)-poly(L-histidine) copolymer micelles (PEG-PHis micelles), either empty, loaded with the drug doxorubicin (DOX), or the fluorophore Rhodamine-B (RB) for imaging purposes. Cellular association of the micelles, in vitro effects on proliferation and cytotoxicity, as well as ex vivo and in vivo responses on tumor growth are assessed. The results indicate that trastuzumab (TZM) conjugation enhances the specific cellular association of PEG-PHis micelles in HER2 overexpressing cells and improves the cytotoxic effects of the micelles themselves. Although the TZM conjugation of DOX-loaded micelles did not contribute to an enhancement in overall efficacy in cell lines and tumor explant cultures, the findings highlight the potential of TZM conjugation on these micelles in targeting HER2-positive tumors.en_US
dc.identifier.citationVasalakumari R, Pandya AD, Pettersen SJ, Kvalvaag ASM, Myrann A, Ghiarasim R, Rotaru A, Dimofte M, Skotland T, Sandvig K, Mælandsmo GM, Iversen TG. Evaluation of HER2 Targeted Poly(Ethylene Glycol)-Poly(L-histidine) Copolymer Micelles in Breast Cancer Models. Macromolecular Bioscience. 2025en_US
dc.identifier.cristinIDFRIDAID 2396898
dc.identifier.doihttps://doi.org/10.1002/mabi.202500047
dc.identifier.issn1616-5187
dc.identifier.issn1616-5195
dc.identifier.urihttps://hdl.handle.net/10037/37982
dc.language.isoengen_US
dc.publisherWileyen_US
dc.relation.journalMacromolecular Bioscience
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2025 The Author(s)en_US
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0en_US
dc.rightsAttribution-NonCommercial 4.0 International (CC BY-NC 4.0)en_US
dc.titleEvaluation of HER2 Targeted Poly(Ethylene Glycol)-Poly(L-histidine) Copolymer Micelles in Breast Cancer Modelsen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)
Except where otherwise noted, this item's license is described as Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)